Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 56, Issue 11, Pages 3014-3019Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201700078
Keywords
cancer therapy; graphene; immune system; myelomonocytic leukemia; nanomaterials
Categories
Funding
- Italian Association against Leukemia (AIL)
- Centre National de la Recherche Scientique
- Ministerio de Economia v competitividad [CTI12014-53600-R]
- Japan Society for the Promotion of Science through a Research Fellowship for Young Scientists [24006076]
- EU [604391]
- MIUR JTC Graphene
- Grants-in-Aid for Scientific Research [17K11733, 26861616] Funding Source: KAKEN
Ask authors/readers for more resources
In the cure of cancer, a major cause of today's mortality, chemotherapy is the most common treatment, though serious frequent challenges are encountered by current anticancer drugs. We discovered that few-layer graphene (FLG) dispersions have a specific killer action on monocytes, showing neither toxic nor activation effects on other immune cells. We confirmed the therapeutic application of graphene on an aggressive type of cancer that is myelomonocytic leukemia, where the monocytes are in their malignant form. We demonstrated that graphene has the unique ability to target and boost specifically the necrosis of monocytic cancer cells. Moreover, the comparison between FLG and a common chemotherapeutic drug, etoposide, confirmed the higher specificity and toxicity of FLG. Since current chemotherapy treatments of leukemia still cause serious problems, these findings open the way to new and safer therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available